NSEGeneral Updates2 Sept 2026 · 2 Sept 2026, 05:32 pm
General Updates
Supriya Lifescience Limited · SUPRIYA
✦ AI SummaryLitigation
Supriya Lifescience Limited has informed the Exchange about the ongoing judicial proceedings of its General Manager – Sales & Marketing, which are still sub judice and awaiting hearing and adjudication. The company will inform the Stock Exchanges of any material development, including any order passed by the Hon’ble Court, as and when received.
Analysis Scores
Earnings Impact2/10
Growth Catalyst1/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Supriya Lifescience Limited has informed the Exchange about General Updates
Attachments (1)
📄pdf
Download →
SUPRIYA_02092026173002_IntimationonJudicialCustody020926.pdf
View document text
September 02, 2025
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block,
Dalal Street, Bandra-Kurla Complex
Mumbai- 400 001. Bandra (E), Mumbai - 400 051.
Scrip Code: 543434 NSE Symbol: SUPRIYA
Dear Sir/Madam,
With reference to our earlier intimation dated July 4, 2026, submitted to the Stock Exchanges pursuant
to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015, regarding the judicial proceedings of our General Manager – Sales & Marketing, in the matter, we
wish to inform you that the matter continues to remain sub judice and is awaiting hearing and
adjudication before the Hon’ble Court of Law. The Company had informed the current status of the case
to Investors through its Earnings call and its Transcript submitted to Stock Exchanges on August 14,
2026, and August 18, 2026, respectively.
As on date, there has been no further development or order passed by the Hon’ble Court in the matter.
The Company shall continue to monitor the matter and will duly inform the Stock Exchanges of any
material development, including any order passed by the Hon’ble Court, as and when received by the
Company, in accordance with the applicable regulatory requirements.
You are requested to kindly take the above information on record.
Thanking you,
For Supriya Lifescience Limited
Prachi Sathe
Company Secretary & Compliance Officer
Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com
Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com
GOVT. RECOGNISED EXPORT HOUSE